Roy Vagelos Net Worth 2026: How He Built a $12.5B Empire

Career Milestones That Built His Fortune

Roy Vagelos’ journey from a Greek-American medical student to a pharmaceutical billionaire began in 1956 when he joined the National Institutes of Health (NIH). His early work on cholesterol metabolism laid the foundation for his later breakthroughs. By 1975, he had become the Director of Basic Research at Merck & Co., where he led the discovery of Mevacor (lovastatin), the first statin drug to combat high cholesterol. Launched in 1987, Mevacor generated over $12 billion in revenue for Merck, directly contributing to Vagelos’ wealth.

From 1985 to 1994, Vagelos served as Merck’s president and CEO, overseeing the development of other blockbuster drugs like Zovirax (for herpes) and Foscamet (for AIDS-related infections). His leadership transformed Merck into a global pharmaceutical giant, significantly boosting his personal net worth. Even after leaving Merck, his influence persisted through board roles and strategic investments, including his stake in Regeneron Pharmaceuticals.

Regeneron Stock: The $295M Wealth Engine

As of June 3, 2026, Roy Vagelos owns 438,071 shares of Regeneron Pharmaceuticals (REGN), valued at over $295.1 million. This stock portfolio constitutes a significant portion of his net worth, though it represents only his personal holdings. Since 2021, he has sold 38,611 shares of REGN, netting approximately $26.5 million. His most recent transaction occurred on March 30, 2022, when he sold 14,286 shares.

The volatility of Regeneron’s stock price directly impacts his net worth. For example, a 10% drop in REGN’s share price would reduce his holdings by $29.5 million. Conversely, a rise in Regeneron’s stock value could elevate his net worth to $325 million or more. This underscores the importance of stock market trends in assessing his financial status.

Merck & Co.: From Mevacor to Billionaire

Merck’s role in Vagelos’ financial success cannot be overstated. During his tenure as CEO, Mevacor became one of the most profitable drugs in history. By 2000, it had generated $12.5 billion in cumulative revenue, with Merck capturing over 70% of the global statin market. Vagelos’ leadership also extended to the development of Mectizan (ivermectin), a drug donated to eradicate river blindness in Africa. While this act of corporate philanthropy boosted Merck’s reputation, it also indirectly enhanced Vagelos’ personal brand and, by extension, his marketability as a pharmaceutical leader.

Forbes’ 2024 Billionaires list ranked Vagelos at #2692 with a net worth of $1 billion. This figure likely reflects a combination of his Merck-era earnings, stock sales, and continued investments. However, Merck’s historical success remains a cornerstone of his wealth, even as he pivots toward Regeneron’s growth in biotechnology.

Philanthropy vs. Net Worth: The $100M River Blindness Donation

Vagelos’ philanthropy is as notable as his wealth. In 1998, he and Merck committed to donating Mectizan to combat river blindness (onchocerciasis), a parasitic disease affecting millions in Africa. By 2026, this initiative had distributed over 3.5 billion doses, preventing blindness in an estimated 17 million people. While this donation cost Merck $100 million annually, it enhanced Vagelos’ public image and aligned with his belief in corporate social responsibility.

However, philanthropy does not directly reduce net worth. Vagelos’ $100 million contribution to the Mectizan program is classified as a non-cash donation, meaning it does not appear on his personal financial statements. Instead, his wealth remains tied to liquid assets like Regeneron stock and real estate holdings, which are not detailed in public records.

Key Net Worth Discrepancies: Why Sources Conflict

The variation in Vagelos’ reported net worth—ranging from $295.1 million to $12.5 billion—stems from differing methodologies. QuiverQuant and GuruFocus focus on his stock holdings and recent transactions, while Cine Net Worth aggregates combined wealth with his spouse, Diana. For example:

• QuiverQuant (June 2026): $295.1M (REGN shares)
• GuruFocus (2025): $579M (REGN shares + undisclosed assets)
• Cine Net Worth (2025): $12.5B (combined with Diana)

These discrepancies highlight the challenges of tracking real-time net worth for high-net-worth individuals whose assets include private equity, real estate, and non-publicly traded stocks.

10+ Key Facts About Roy Vagelos’ Wealth

1. Birth and Early Career

Born on October 8, 1929, in New York City, Vagelos earned his MD from Columbia University and trained at the NIH before joining Merck in 1975.

2. Mevacor’s Financial Impact

Mevacor, launched in 1987, became Merck’s top-selling drug, generating $12.5 billion in revenue by 2000 and securing Vagelos’ financial future.

3. Forbes’ 2024 Billionaire Status

Vagelos made Forbes’ 2024 World’s Billionaires list for the first time, with a net worth of $1 billion, attributed to his Merck and Regeneron holdings.

4. Regeneron Stock Holdings

As of June 2026, he owns 438,071 shares of Regeneron, valued at over $295.1 million, making it his largest asset.

5. Stock Sales Since 2021

Vagelos has sold 38,611 REGN shares since 2021, netting $26.5 million, including a 14,286-share sale on March 30, 2022.

6. Combined Net Worth with Diana

Vagelos and his spouse, Diana, have a combined net worth of $12.5 billion as of 2025, though this includes assets not tied to his personal income.

7. Philanthropy and Mectizan

Merck’s Mectizan donation program, spearheaded by Vagelos, has distributed 3.5 billion doses to combat river blindness in Africa.

8. Leadership at Merck

Vagelos served as Merck’s CEO from 1985 to 1994, during which the company developed Zovirax and Foscamet, two of its most successful drugs.

9. Real Estate and Other Assets

While his Regeneron and Merck holdings are public, Vagelos’ real estate and private equity investments are not disclosed, adding to net worth uncertainties.

10. Age and Legacy

At 96 years old, Vagelos remains a key figure in pharmaceutical innovation, with his legacy defined by both wealth and public health contributions.

FAQ: Net Worth, Stock Sales, and Philanthropy

1. How did Roy Vagelos become a billionaire?

Vagelos amassed his wealth through the development of Mevacor (Merck’s top-selling drug), leadership roles at Merck & Co., and strategic investments in Regeneron Pharmaceuticals.

2. What is Roy Vagelos’ net worth in 2026?

As of June 2026, his net worth is estimated at $295.1 million based on his 438,071 shares of Regeneron, though combined wealth with Diana is $12.5 billion.

3. How does Regeneron Pharmaceuticals contribute to his wealth?

Regeneron is Vagelos’ largest asset, with 438,071 shares valued at over $295.1 million. He has sold 38,611 shares since 2021, netting $26.5 million.

4. What role did Merck & Co. play in his financial success?

Merck’s Mevacor, Zovirax, and Foscamet generated billions in revenue. Vagelos’ leadership from 1985–1994 positioned him as a pharmaceutical industry titan.

5. Why do different sources report conflicting net worth figures?

Discrepancies arise from methodologies: QuiverQuant focuses on stock holdings, GuruFocus includes additional assets, and Cine Net Worth aggregates combined wealth with Diana.

6. What philanthropy efforts has Roy Vagelos funded?

Vagelos spearheaded Merck’s Mectizan donation program, donating over $100 million annually to combat river blindness in Africa since 1998.

7. How many shares of Regeneron does Roy Vagelos own?

As of June 2026, he owns 438,071 shares of Regeneron Pharmaceuticals (REGN), valued at over $295.1 million.

8. How does Roy Vagelos’ net worth compare to other physician billionaires?

Vagelos ranks among the wealthiest physician billionaires, with a net worth exceeding $1 billion (Forbes, 2024) and combined assets reaching $12.5 billion.

Year	REGN Shares Sold	Proceeds (Est.)
2021	5,000	$3.5M
2022	14,286	$8.5M
2025	19,325	$18M

Drug	Launch Year	Revenue (Cumulative)
Mevacor	1987	$12.5B
Zovirax	1988	$3.8B
Foscamet	1994	$1.2B

Conclusion: Reconciling Wealth, Legacy, and Philanthropy

Roy Vagelos’ net worth is a complex tapestry of pharmaceutical innovation, strategic investments, and corporate philanthropy. While public records peg his personal net worth at $295.1 million (as of June 2026), his combined wealth with Diana Vagelos reaches $12.5 billion. This disparity underscores the importance of context when evaluating net worth: his Regeneron stock holdings represent liquid assets, while his legacy at Merck and contributions to public health are intangible yet equally significant.

Vagelos’ career demonstrates how breakthroughs in medicine can translate into financial success. From Mevacor’s $12.5 billion revenue to Regeneron’s biotech boom, his financial trajectory is intertwined with scientific progress. Yet, his philanthropy—most notably the Mectizan donation program—reminds us that wealth is not merely a measure of personal gain but also a tool for societal impact. As he approaches his 97th birthday, Vagelos remains a symbol of how leadership, innovation, and generosity can coexist in the pharmaceutical world.